Echolight joins National Osteoporosis Foundation’s Corporate Advisory Roundtable
Innovator in bone density diagnostic technology brings expertise to foundation.
SEATTLE, Feb. 23, 2021 /PRNewswire/ — Echolight Medical, manufacturer of the radiation-free EchoS portable densitometer, has joined the National Osteoporosis Foundation (NOF) Corporate Advisory Roundtable. Focusing on bone health and patient access, NOF’s corporate roundtable advises the board of trustees and develops initiatives to address “the fundamental forces affecting the public’s access to osteoporosis information and medical care.”
“We are pleased to contribute to this influential group and be in a position to truly have an impact,” said Doug Tefft, president of Echolight USA (launched September 2020). “It’s a privilege to join this group of accomplished leaders working across the osteoporosis field – we firmly believe these partnerships and shared passions will expand health care access to many more people.”
EchoS, widely used throughout Europe, is the first radiation-free, portable bone densitometer used to regularly monitor key bone health indicators. Using Radiofrequency Echographic Multi Spectrometry (REMS) to analyze ultrasound signals, patients know their bone health scores and future fracture risk within minutes. REMS is more cost-efficient, accessible, and accurate than the current bone mineral density measurement technology, DXA.
“It’s important to have innovative companies and technologies included in our discussions to help bring about better outcomes for patients,” said Claire Gill, CEO of the National Osteoporosis Foundation. “We look forward to working with Echolight on efforts to substantially increase osteoporosis screenings in the U.S.”
More than half of Americans age 50 and older have a high-risk of bone fracture, making osteoporosis and osteopenia an urgent public health issue. It is especially prominent in women, as pregnancy and menopause can cause bone density loss. Chronic conditions such as diabetes, rheumatoid arthritis, kidney or liver disease, cancer, HIV and lupus, and medications to treat these and other ailments also cause increased risk of fracture. More women die annually from the effects of osteoporosis than breast and cervical cancer combined. REMS can help in early and accurate diagnosis to make informed bone health decisions and enhance quality of life.
For more information:
New important recognition for Echolight: REMS technology (Radiofrequency Echographic Multi Spectrometry), the first ultrasound-based method to diagnose the osteoporosis and assess the risk of fragility fractures, is officially included in the Inter-Company Ministerial...
Echolight took part in the annual convention of the American Society for Bone and Mineral Research (ASBMR) in San Diego, California. This eagerly awaited meeting took place from 1st to 4th October 2021 and that involved more than 3,000 experts from all over the world...
Echolight Medical awarded Vizient contract to provide improved technology in bone density diagnostics. Echolight Medical, an innovator in bone health technology, has been awarded a multi-year contract with Vizient Inc,, to make its Radiofrequency Echographic Multi...